Bigfinite, a San Francisco, CA-based provider of data analytics and AI solutions for optimizing the pharmaceutical manufacturing process, raised $8.5m in seed financing.
The round was led by Crosslink Capital, Uncork Capital (formerly SoftTech VC) and La Famiglia, with participation from Industry Ventures and Krohne. In conjunction with the funding, Omar El-Ayat, Partner, Crosslink Capital and Andy McLoughlin, Partner, Uncork Capital (formerly SoftTech VC) will join Bigfinite’s Board of Directors.
The company plans to use the capital to expand its business development and customer support efforts.
Founded in 2013 by Pep Gubau, CEO, Bigfinite provides data analytics and AI solutions for optimizing the pharmaceutical manufacturing process. Its Bigengine SaaS platform enables pharma companies to discover new ways to optimize processes, reduce manufacturing quality issues, and enhance regulatory compliance. The company also just launched its new version of Bigengine (Bigifnite AI SaaS Platorm for Pharma Manufacturing, v 1.5). This version includes a drag and drop solutions editor and five new solutions: Predictive Maintenance, Predictive OEE, Golden Batch, Energy efficiency and Causality Detection.
Bigfinite has 32 employees between its US office in San Francisco, Calif. and its European office in Barcelona, Spain, and expects to double in size by the end of Q2 2018.